4-Hydroxythiobenzamide CAS 25984-63-8 Purity >99.0% (HPLC) Febuxostat Intermediate Factory

Short Description:

Chemical Name: 4-Hydroxythiobenzamide

CAS: 25984-63-8

Purity: >99.0% (HPLC)

Appearance: Pale Yellow Solid Powder

Intermediate of Febuxostat (CAS: 144060-53-7)

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Ruifu Chemical Supply Febuxostat Related Intermediates:
Febuxostat CAS 144060-53-7
Ethyl 2-Chloroacetoacetate CAS 609-15-4
4-Hydroxythiobenzamide CAS 25984-63-8
Ethyl 2-(3-Cyano-4-Hydroxyphenyl)-4-Methyl-1,3-Thiazole-5-Carboxylate CAS 161798-02-3
Ethyl 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5-Thiazolecarboxylate CAS 160844-75-7
Ethyl 2-(3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-01-2
Ethyl 2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-03-4
Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161797-99-5

Chemical Properties:

Chemical Name	4-Hydroxythiobenzamide
Synonyms	p-Hydroxythiobenzamide; 4-Hydroxy-thiobenzamide; p-Hydroxythio-benzamide; 4-Hydroxybenzenecarbothioamide; 4-Hydroxybenzothioamide
CAS Number	25984-63-8
CAT Number	RF-PI1855
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C7H7NOS
Molecular Weight	153.20
Melting Point	181.0~185.0℃
Density	1.338±0.06 g/cm3
Solubility (Soluble in)	Soluble in Methanol
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	Pale Yellow Solid Powder
Purity / Analysis Method	>99.0% (HPLC)
Identification	By HPLC; By HNMR
Loss on Drying	<0.50%
Residue on Ignition	<0.20%
Single Impurity	<0.50%
Total Impurities	<1.00%
Test Standard	Enterprise Standard
Usage	Intermediate of Febuxostat (CAS: 144060-53-7)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

Application:

4-Hydroxythiobenzamide (CAS: 25984-63-8) can be used as an intermediate of Febuxostat (CAS: 144060-53-7). Febuxostat, a selective xanthine oxidase inhibitor, was launched for the chronic management of hyperuricemia in patients with gout. Hyperuricemia is defined as a serum uric acid concentration exceeding the limit of solubility. It predisposes affected persons to gout, a disease characterized by the formation of crystals of monosodium urate or uric acid from supersaturated fluids in joints and other tissues.